<DOC>
	<DOCNO>NCT00484809</DOCNO>
	<brief_summary>This postmarketing surveillance study evaluate safety profile Enbrel ( etanercept ) Indian population . It provide surveillance currently approve indication Enbrel reduce symptom inhibit progression structural damage patient moderately severely active rheumatoid arthritis .</brief_summary>
	<brief_title>Study Evaluating Tolerance Safety Enbrel ( Etanercept ) Adults Children</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion study per approve indication package insert . Patients moderately severely active RA . Children JRA inadequate response one DMARDs . Known hypersensitivity etanercept component . Known significant concurrent medical disease , include : Congestive heart failure , uncontrolled angina pectoris , recent history myocardial infarction Cancer history cancer Active infection Sepsis risk sepsis Active tuberculosis past history tuberculosis Pancytopenia Females pregnant , breast feeding risk pregnancy use medically acceptable form contraception . Patients plan undergo elective surgery study period .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>juvenile rheumatoid arthritis</keyword>
</DOC>